Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension

First-line treatment of severe pre-capillary pulmonary hypertension with sub-cutaneous treprostinil is safe and efficacious over many years. If up-titration beyond 6 months is tolerated, effective doses are reached and outcomes are good.